| 3.2 0.47 (17.22%) | 06-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.44 | 1-year : | 3.79 |
| Resists | First : | 2.94 | Second : | 3.25 |
| Pivot price | 2.75 |
|||
| Supports | First : | 2.45 | Second : | 2.04 |
| MAs | MA(5) : | 2.64  |
MA(20) : | 2.76 |
| MA(100) : | 2.99 |
MA(250) : | 2.85 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 29.2 |
| RSI | RSI(14): 41.1 |
|||
| 52-week | High : | 4.75 | Low : | 1.92 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OCX ] has closed above bottom band by 22.0%. Bollinger Bands are 30.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.69 - 2.71 | 2.71 - 2.72 |
| Low: | 2.42 - 2.44 | 2.44 - 2.46 |
| Close: | 2.54 - 2.57 | 2.57 - 2.59 |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Tue, 17 Jun 2025
OncoCyte Rebrands to Insight Molecular Diagnostics - TipRanks
Tue, 17 Jun 2025
Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville - GlobeNewswire
Tue, 25 Mar 2025
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo Finance
Mon, 24 Mar 2025
OncoCyte (OCX) Reports Successful 2024; Sets Stage for 2025 Catalysts - StreetInsider
Fri, 14 Mar 2025
OncoCyte Corporation (OCX): Among Top Insider Purchases Last Month - Yahoo Finance
Wed, 08 Jan 2025
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 7.75e+006 (%) |
| Held by Institutions | 22 (%) |
| Shares Short | 327 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.158e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -273.1 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -429 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 115.95 |
| Sales Per Share | 3.87879e+006 |
| EBITDA (p.s.) | 2.11111e+006 |
| Qtrly Earnings Growth | -3.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 7.06 |
| Dividend | 0 |
| Forward Dividend | 265490 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|